Literature DB >> 7052160

Pathologic effects of plasma from patients with thrombotic thrombocytopenic purpura on platelets and cultured vascular endothelial cells.

E R Burns, D Zucker-Franklin.   

Abstract

The pathologic hallmarks of thrombotic thrombocytopenic purpura (TTP) include endothelial cell proliferation and subendothelial hyalin deposits in the microvasculature leading to symptomatic thrombotic occlusions. Plasma or sera from three consecutive patients with TTP were subjected to multiple analyses to determine whether they induce endothelial injury and/or platelet activation, two pathogenic mechanisms that may account for this disorder. Sera were utilized in a microcytotoxicity assay against cultured human umbilical vein endothelial cells (EC). These cells were assessed ultrastructurally and with immunofluorescence techniques to ascertain the nature of inflicted cell damage. Control plasmas were obtained from healthy volunteers as well as patients with immune complex disease and the adult hemolytic uremic syndrome. In the presence of TTP serum, cell kill of 3H-proline-labeled EC averaged 42% versus 8.6% for control sera. Cytotoxicity induced by an IgG fraction of TTP sera averaged 70% versus 16.8% for control IgG. Removal of IgG by immune precipitation diminished cytotoxicity by 70%. Using indirect immunofluorescence, IgG was detected on EC incubated with TTP serum but not on EC treated with control serum. Ultrastructural changes became apparent within 30 min after exposure of cultured EC to TTP serum. Virtually every cell developed numerous cytoplasmic inclusions rarely seen in EC in the presence of normal serum. Prolonged incubation with the TTP serum led to progressive cytolysis, terminating with complete cytoplasmic and nuclear degeneration. Plasma from all three patients with TTP caused spontaneous aggregation of normal washed platelets as monitored by aggregometry. No spontaneous aggregation occurred in response to control plasmas. These results indicate that the sera of the three TTP patients studied were able to mediate time-dependent immune destruction of human cultured endothelial cells and that their plasmas were capable of causing spontaneous aggregation of normal human platelets in vitro. It would seem likely that these mechanisms are also operative in vivo to produce the endothelial destruction as well as the thrombotic vascular occlusions seen in this disorder.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7052160

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

Review 1.  Glomerular fibrin deposition and removal.

Authors:  J M Bergstein
Journal:  Pediatr Nephrol       Date:  1990-01       Impact factor: 3.714

Review 2.  Anti-neutrophil cytoplasmic antibodies and anti-endothelial cell antibodies.

Authors:  M J Dillon; E J Tizard
Journal:  Pediatr Nephrol       Date:  1991-03       Impact factor: 3.714

Review 3.  Drug-induced thrombotic microangiopathy: incidence, prevention and management.

Authors:  R Pisoni; P Ruggenenti; G Remuzzi
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 4.  Is there a microangiopathic antiphospholipid syndrome?

Authors:  Ronald A Asherson; Sylvia S Pierangeli; Ricard Cervera
Journal:  Ann Rheum Dis       Date:  2007-04       Impact factor: 19.103

Review 5.  Hemolytic uremic syndrome.

Authors:  B R Nammalwar; N Balasubramanian; C Thangadurai; B R Santhanakrishnan
Journal:  Indian J Pediatr       Date:  1987 Sep-Oct       Impact factor: 1.967

6.  P. falciparum infected erythrocytes are capable of endocytosis.

Authors:  E R Burns; S Pollack
Journal:  In Vitro Cell Dev Biol       Date:  1988-05

Review 7.  Anti-endothelial cell antibodies and autoimmune diseases.

Authors:  N Del Papa; D Gambini; P L Meroni
Journal:  Clin Rev Allergy       Date:  1994

8.  Haemolytic uraemic syndrome.

Authors:  M Levin; J M Barratt
Journal:  Arch Dis Child       Date:  1984-05       Impact factor: 3.791

9.  Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.

Authors:  H M Tsai; E C Lian
Journal:  N Engl J Med       Date:  1998-11-26       Impact factor: 91.245

Review 10.  Pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.